Singapore's Venture Corporation (SGX:V03) has delivered a robust 38% total shareholder return over the past year, buoyed by dividends. However, a closer look reveals declining earnings and revenue, raising questions about the sustainability of its recent market favor and its longer-term trajectory.
As a significant equity rotation takes hold in early 2026, shifting focus from growth to value, dividend-focused ETFs are emerging as key beneficiaries for investors seeking yield and stability.
Glaukos Corporation's iDose TR glaucoma therapy receives a key FDA labeling update, permitting repeat administration. While the news bolsters the company's growth narrative, analysts are divided on whether its current stock price already reflects future potential amid rich valuation metrics.
Goldcom's (GOLD) shares have soared nearly 90% in the past year, leaving investors to grapple with a critical question: has the market already priced in all the good news, or is there still room to run? A deep dive into the valuation metrics reveals a stark contradiction.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
Bayer's share price has more than doubled in the past 12 months, yet key valuation models suggest a significant gap remains between its market price and intrinsic value. We examine the metrics behind the rally and the lingering legal and portfolio challenges facing the company.
In a major strategic shift, UPS announced plans to eliminate up to 30,000 positions and close 24 facilities by 2026. The logistics giant is restructuring its network to prioritize automation and higher-margin business segments, while scaling back lower-margin volume, notably from Amazon. The move aims to reshape the company's cost structure and profitability profile amid a challenging multi-year stock performance.
A software engineer who turned an early bet on Nvidia into a $20 million fortune and early retirement is now pointing to quantum computing as the frontier with similar explosive potential. His journey underscores the high-risk, high-reward nature of thematic investing.
Investors in Malaysian construction giant WCT Holdings Berhad have enjoyed a 37% return over the past three years, significantly outpacing the broader market, even as the stock faces recent headwinds. Analysis suggests the company's transition to profitability may underpin its longer-term performance.
Shares of Brookdale Senior Living (BKD) have skyrocketed over 224% in the past year, drawing intense scrutiny from investors. As the stock hovers near analyst targets, the market debates whether its valuation still has room to run or if it's overheated in the face of sector headwinds.
BeOne Medicines (ONC) presents a complex picture for investors, with recent short-term volatility contrasting sharply with strong long-term returns. As the stock trades around $340, analysts debate whether its current price fully reflects the ambitious growth narrative in its oncology pipeline.
While both ETFs target the high-flying U.S. technology sector, a closer look reveals critical distinctions in diversification, concentration risk, and liquidity that could sway long-term portfolio outcomes.
Amid a steep 60% annual share price decline, investment firm Chicago Capital has significantly reduced its position in PROCEPT BioRobotics, a developer of robotic systems for urological surgery, signaling a portfolio risk reassessment.
New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
Biotech firm Definium Therapeutics appoints seasoned commercial executive Roger Adsett to its board, signaling a strategic shift towards commercialization as key late-stage trial data approaches.
Tilray Brands deepens its commitment to Europe's regulated medical cannabis sector with the launch of Tilray Medical Italia, a strategic venture with local partner Molteni Farmaceutici. The move comes as the company seeks to stabilize its growth narrative amid significant stock market volatility.
After a powerful 41% surge over the past year, Lattice Semiconductor (LSCC) finds itself at a crossroads. With shares trading near $80, new analysis suggests the stock may be significantly overvalued, raising questions about its long-term prospects in the competitive semiconductor landscape.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
Shares of Charter Communications jumped more than 7% Friday after the telecom giant reported a smaller-than-anticipated decline in internet subscribers for the fourth quarter, signaling resilience in its core business amid industry-wide pressures.
Boeing's Wichita-based engineering union has overwhelmingly approved a new labor agreement, securing substantial pay raises and improved benefits for approximately 1,600 technical staff, many recently transitioned from Spirit AeroSystems.
